相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Prolonged Use of Nimotuzumab in Children with Central Nervous System Tumors: Safety and Feasibility
Ricardo Cabanas et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2014)
Autophagic activation with Nimotuzumab enhanced chemosensitivity and radiosensitivity of esophageal squamous cell carcinoma
Haizhu Song et al.
EXPERIMENTAL BIOLOGY AND MEDICINE (2014)
Radiotherapy with concurrent cisplatin-based doublet or weekly cisplatin for cervical cancer: A systematic review and meta-analysis
Fausto Petrelli et al.
GYNECOLOGIC ONCOLOGY (2014)
Improved Survival with Bevacizumab in Advanced Cervical Cancer
Krishnansu S. Tewari et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Trial Watch Tumor-targeting monoclonal antibodies in cancer therapy
Erika Vacchelli et al.
ONCOIMMUNOLOGY (2014)
Phase II study of temsirolimus (CCI-779) in women with recurrent, unresectable, locally advanced or metastatic carcinoma of the cervix. A trial of the NCIC Clinical Trials Group (NCIC CTG IND 199)
A. V. Tinker et al.
GYNECOLOGIC ONCOLOGY (2013)
Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer
Israel Zighelboim et al.
GYNECOLOGIC ONCOLOGY (2013)
Emerging drugs for cervical cancer
Alfonso Duenas-Gonzalez et al.
EXPERT OPINION ON EMERGING DRUGS (2012)
Phase II trial of nab-paclitaxel in the treatment of recurrent or persistent advanced cervix cancer: A gynecologic oncology group study
David S. Alberts et al.
GYNECOLOGIC ONCOLOGY (2012)
Outcomes and prognosis of patients with recurrent cervical cancer after radical hysterectomy
Jian-Tai Qiu et al.
GYNECOLOGIC ONCOLOGY (2012)
(Laterally) Extended Endopelvic Resection: Surgical treatment of locally advanced and recurrent cancer of the uterine cervix and vagina based on ontogenetic anatomy
Michael Hoeckel et al.
GYNECOLOGIC ONCOLOGY (2012)
Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer
Dirk Strumberg et al.
INVESTIGATIONAL NEW DRUGS (2012)
Epidermal growth factor receptor as a biomarker for cervical cancer
T. Soonthornthum et al.
ANNALS OF ONCOLOGY (2011)
Cetuximab monotherapy in advanced cervical cancer: a retrospective study with five patients
Linda Hertlein et al.
ARCHIVES OF GYNECOLOGY AND OBSTETRICS (2011)
Don't jump to rash conclusions
Gwyn Bebb et al.
CANCER BIOLOGY & THERAPY (2011)
Bivalent binding by intermediate affinity of nimotuzumab A contribution to explain antibody clinical profile
Greta Garrido et al.
CANCER BIOLOGY & THERAPY (2011)
Nimotuzumab for pediatric diffuse intrinsic pontine gliomas
Maura Massimino et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2011)
Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study
Alessandro D. Santin et al.
GYNECOLOGIC ONCOLOGY (2011)
Conservative management of early stage cervical cancer: Is there a role for less radical surgery?
Kathleen M. Schmeler et al.
GYNECOLOGIC ONCOLOGY (2011)
Phase III, Open-Label, Randomized Study Comparing Concurrent Gemcitabine Plus Cisplatin and Radiation Followed by Adjuvant Gemcitabine and Cisplatin Versus Concurrent Cisplatin and Radiation in Patients With Stage IIB to IVA Carcinoma of the Cervix
Alfonso Duenas-Gonzalez et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Evaluation of pemetrexed (Alimta, LY231514) as second-line chemotherapy in persistent or recurrent carcinoma of the cervix: the CERVIX 1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group
D. Lorusso et al.
ANNALS OF ONCOLOGY (2010)
Nimotuzumab with chemoradiation confers survival advantage in treatment naive head and neck tumors overexpressing EGFR
Chetana Basavaraj et al.
CANCER BIOLOGY & THERAPY (2010)
Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck
Marta Osorio Rodriguez et al.
CANCER BIOLOGY & THERAPY (2010)
Pharmacodynamic Trial of Nimotuzumab in Unresectable Squamous Cell Carcinoma of the Head and Neck: A SENDO Foundation Study
Federico Rojo et al.
CLINICAL CANCER RESEARCH (2010)
A phase II study of sunitinib in patients with locally advanced or metastatic cervical carcinoma: NCIC CTG Trial IND.184
Helen J. Mackay et al.
GYNECOLOGIC ONCOLOGY (2010)
Health-related quality of life outcomes associated with four cisplatin-based doublet chemotherapy regimens for stage IVB recurrent or persistent cervical cancer: A Gynecologic Oncology Group study
David Cella et al.
GYNECOLOGIC ONCOLOGY (2010)
Nimotuzumab: a novel anti-EGFR monoclonal antibody that retains anti-EGFR activity while minimizing skin toxicity
William Kells Boland et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2009)
Lack in Efficacy for Imatinib Mesylate as Second-Line Treatment of Recurrent or Metastatic Cervical Cancer Expressing Platelet-Derived Growth Factor Receptor α
Myrna Candelaria et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2009)
A Phase II Trial of Erlotinib in Recurrent Squamous Cell Carcinoma of the Cervix A Gynecologic Oncology Group Study
Russell J. Schilder et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2009)
Phase III Trial of Four Cisplatin-Containing Doublet Combinations in Stage IVB, Recurrent, or Persistent Cervical Carcinoma: A Gynecologic Oncology Group Study
Bradley J. Monk et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Enhancement of the antitumor activity of ionising radiation by nimotuzumab, a humanised monoclonal antibody to the epidermal growth factor receptor, in non-small cell lung cancer cell lines of differing epidermal growth factor receptor status
Y. Akashi et al.
BRITISH JOURNAL OF CANCER (2008)
A phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer
A. Goncalves et al.
GYNECOLOGIC ONCOLOGY (2008)
Oncologic outcome of fertility-sparing radical trachelectomy versus radical hysterectomy for stage IB1 cervical carcinoma
John P. Diaz et al.
GYNECOLOGIC ONCOLOGY (2008)
Evaluation of pegylated liposomal doxorubicin (Doxil) as second-line chemotherapy of squamous cell carcinoma of the cervix: A phase II study of the Gynecologic Oncology Group
Peter G. Rose et al.
GYNECOLOGIC ONCOLOGY (2006)
Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients
T Crombet et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Antiproliferative, antiangiogenic and proapoptotic activity of h-R3:: A humanized anti-EGFR antibody
T Crombet-Ramos et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
分享论文
